top of page
Atorvia CMYK.jpg

a commercially focused biotech

revolutionizing treatment for people with organ failure 

Atorvia is developing, advancing and commercializing novel drug candidates with the potential to transform the lives of people with organ failure.  Initially targeting the kidney, Atorvia's renal franchise is focused on understanding the underlying mechanisms for numerous kidney disorders to help develop therapies to address treatment gaps. 

Our robust pre-clinical program includes a therapeutic platform targeting nucleophosmin (NPM), an essential protein which becomes toxic when the cell is injured, inducing the regulated cell death pathway that leads to organ failure.  We have a first-in-class drug in development that prevents and treats NPM-induced cell death forming a key building block of our kidney franchise.  Given the high unmet medical need, the first indication we are pursuing is Acute Kidney Injury (AKI) where we have already demonstrated efficacy, safety and survival benefit in pre-clinical studies and are advancing a peptide therapeutic towards IND.  This common and often fatal condition leaves surviving patients with cardio-renal diseases, often leading to stroke, myocardial infarction, chronic kidney disease or end stage renal disease. There is currently no treatment available. 

A biotech with a difference, we integrate market access & commercial strategies at all stages to translate great science into transformative technologies that regulators will approve, payers will pay and physicians will adopt.

Our people

A biotech with a difference, we are on a journey to positively change the lives of patients by ensuring our programs incorporate commercial strategies from the outset.  We believe that being unique is powerful, and this applies as much to our people as it does to our strategy, so we are building a company that celebrates diversity and a culture where difference is valued.  Although we are small, we are mighty, and we approach our work fearlessly.  An inclusive workplace with a global mindset, we welcome people to join us on our journey who will be themselves.    

If you’re driven to perform, you’ll fit right in.  We are nimble, learn quickly, improve constantly, and celebrate our wins at every turn.  Put simply, we hire the best, then let you shine.

If you are interested in joining us on our journey, please contact us here.


Our Approach

Our approach is to apply a market access & commercial lens early and iteratively throughout the entire development process as we build a robust franchise, initially in the kidney, leveraging our expertise in regulated cell death.  Our assets have clear and compelling clinical & commercial opportunities, broad applications, strong patent protection and clear and determinable pathways to IND, clinical validation, regulatory approval and reimbursement.  

Our therapeutic platform targets nucleophosmin (NPM), a critical Bax chaperone, which we have demonstrated is an essential component in regulated cell death pathways following organ insult.  We have a first-in-class therapeutic in development with compelling in vitro and in vivo data, which targets NPM to prevent and treat ischemic organ damage.  The first indication is in the kidney to prevent and treat Acute Kidney Injury (AKI), a devastating condition which affects over 70 million patients worldwide and for which there is still no effective therapy.  

Meet The Board
We celebrate diversity, and it starts at the top

Still in semi-stealth mode, we can't yet share full details of who is leading the Atorvia team, or those working tirelessly to accelerate our programs, but we can share who sits on our Board.  More to follow!

Our footprint

bottom of page